Company intelligence / Profile preview

Audistimpharma

Mérignac, Nouvelle-Aquitaine, France

Ownership: Private
Development stage: Other

Overview

Audistimpharma markets dietary supplements, notably AUDISTIM® Day/Night, which has demonstrated statistically significant improvement in tinnitus-related handicap and psychological stress in a double-blind placebo-controlled trial (n=114, p=0.0158 for THI improvement at 3 months) and in two prior real-world studies. Effects are greater in permanent tinnitus and also show trends toward improved sleep quality.

Therapeutic areas: NeurologyPsychiatry
Modalities: Non-pharmacological therapySmall moleculeNutraceutical
Industry: Food & Nutrition

Beyond the preview

Go deeper on Audistimpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Audistimpharma.

Explore the full profile